-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED ANNOUNCES SANOVO TRIAL DEMONSTRATED SIGNIFICANT PROGRESSION-FREE SURVIVAL BENEFIT OF ORPATHYS® PLUS TAGRISSO® IN TREATMENT-NAÏVE PATIENTS WITH MET-OVEREXPRESSING EGFR-MUTATED LUNG CANCER IN CHINA

Reuters·08/31/2026 00:00:02

Please log in to view news